AVP Fund: Unlocking the Power of the U.S.–India HealthTech Corridor
AVP is built on a clear conviction: the U.S.–India HealthTech corridor is one of the most promising investment opportunities of the next decade.

Why This Corridor Matters:

• The U.S. is the world leader in early-stage health innovation—with cutting-edge R&D, a strong clinical ecosystem, and an established regulatory system.

• India offers unmatched scale, talent, growing healthcare demand, and the ability to serve global markets—especially the Global South.

Together, they form a powerful combination: innovation from the U.S., and cost-effective scaling and adoption from India.
 

The Opportunity:

• U.S. MedTech startups often struggle to expand globally due to high costs and complex markets.

• India provides a springboard—offering faster approvals, affordable clinical trials, and deep technical talent.

• The Indian MedTech market alone is expected to create $100B+ in value in just five years, driven by rising healthcare needs, demographic shifts, and post-COVID supply chain changes.

• The Talent Shift: A new generation of entrepreneurs with experience in both markets are building world-class solutions from India—designed to scale globally.

 

What AVP Does:
We bridge the critical funding and support gap in early-commercial stage Healthtech ventures—especially those at the intersection of deep tech and regulatory complexity.

1. Our support goes beyond capital:

• Cross-border regulatory and commercialization help.

• Access to U.S. and Indian healthcare ecosystems.

• Strategic guidance toward acquisition or IPO.

2. Our Cross-Border Strategy:

• In the U.S., we invest in high-potential health tech and help scale it affordably in India and the Global South.

• In India, we back top startups and guide them through global validation (like FDA approval) and market entry in places like the U.S.

3. Our Team & Network:

• Led by a Managing Partner with deep U.S. healthcare investing experience.

• Ties with Silicon Valley, Stanford Biodesign, Setu Foundation, U.S. academic centers, Indian public institutions, and forward-looking state governments.

4. Our Pipeline:

• From a long list of Indian startups, we’ve shortlisted ~100 in late-stage development.

• We also track U.S. startups primed for cross-border growth.

• From this pool, we’ll invest in 10–20 standout companies with capital-efficient models, high growth potential, and readiness to scale.

AVP is more than a fund!
It’s a platform to launch transformative health innovations across borders, improve patient outcomes globally, and deliver exponential value to our investors.